9 November 2021 in Health Care of the Russian Federation
Introduction. Digital technologies are an essential condition for the development of modern health care. New forms of interaction between the supplier and the consumer of medical services determine the need to understand the attitude of the doctor and the patient to this employment operation. Purpose. Assess the change in the quality of communications between the doctor and the patient with the widespread introduction of electronic medical records. Material and methods. Within the framework of the project, a content analysis of media materials was held. Mass (questionnaire) survey of doctors and patients in November-December 2020 was executed. The comprehensive survey had 482 respondents, including 168 doctors and 314 patients. Results. Most (61.5%) of medical professionals indicate a decrease in time costs during the patient’s reception, an increase in time to work with patients is noted in 47.4% of respondents. 55% of doctors report that the service helps better focus on the provision of medical care, and 47.6% of respondents believe that the conduct of medical documentation in electronic form allows reducing the frequency of passing a significant pathology. Among patients, 52.2% believe that introducing electronic medical records will enable you to increase the time that the doctor pays to the patient during the reception. 68.9% of patients indicate an improvement in the interaction between doctors and patients. Conclusion. High-quality results can be achieved only if there is a medical staff with the skills of using modern digital technologies and new communication skills with a patient when using electronic medical records.
12 December 2022 in Health Care of the Russian Federation
Introduction. The change in the classical etiological paradigm of hepatocellular carcinoma has led to the fact that non-alcoholic fatty liver disease is now the fastest growing cause of hepatocellular carcinoma in the world. Purpose. To study the range of medicines and analyze the costs of drug provision for a determined population of patients with non-alcoholic fatty liver disease in Moscow over a three-year period. Materials and methods. Based on data from the Moscow Department of Health on preferential drug coverage for the period from 2019 to 2021 the range of drug therapy and the economic costs. Results. For 3 years, seventeen thousand two hundred ten patients with a diagnosis of non-alcoholic fatty liver disease received preferential drug coverage in Moscow, and the amount of costs minus payment by the patient amounted to 49,102,963.97 rubles. The most prescribed drugs were drugs from the group of “hepatoprotectors”. An increase in the population of patients with non-alcoholic fatty liver disease over a three-year period by 1.7 times, an increase in the cost of its drug provision. Along with this, the prevalence in the spectrum of drugs was revealed: glycyrrhizic acid + phospholipids; phospholipids; ursodeoxycholic acid; ademetionine is not found in international practice and is not funded under the nosology “non-alcoholic fatty liver disease”. Limitations. When studying options for drug provision of patients with non -alcoholic fatty liver disease, we had an assessment of 17,210 observations, which is a sufficient reference sample Conclusion. Analysis of the qualitative and quantitative composition of the population of patients with non-alcoholic fatty liver disease can be an effective tool for predicting the social and economic burden of the disease and can be used for rational planning of budget expenditures of all levels.
30 December 2020 in Health Care of the Russian Federation
Introduction. Such medical technology like a direct antiviral drugs for treatment for chronic hepatitis C (CHC) remains inaccessible due to high absolute cost for health care systems, lack of assessment in specific region of Russian Federation and correlation with results of used antiviral therapy options. The purpose of the study is to determine most cost-effective option of drug provision with direct antiviral drugs for the treatment of chronic hepatitis C. Material and methods. Based on the population of chronic hepatitis C adult patients receiving medications at expense of Moscow budget funds, was performed a pharmacoeconomic analysis of drug therapy with direct antiviral drugs. Results.The use of new pangenotypic direct antiviral drugs for the treatment of CHC in a clinically heterogeneous population of Russian adults with 1-6 genotypes of the hepatitis C virus is economically justified. Both alternative scenarios demonstrated an advantage over the baseline scenario in the form of financial savings of 66,028,192. 45 rubles and 83,647,819.27 rubles and an increase in the number of effectively treated patients by 197 and 287 people per year, respectively. Conclusion. An increase in the share of new direct antiviral drugs in drug supply programs will increase the efficiency of the use of financial resources and increase the availability of direct antiviral drugs, which may ultimately lead to the achievement of an epidemiological effect on a population scale.
1 August 2021 in Problems of Social Hygiene, Public Health and History of Medicine
MHM. E. Hołownia-Voloskova
Introduction: Liver cirrhosis is a major but preventable cause of health loss worldwide. The era of «big data» allows us to evaluate this nosology in a new format. Purpose: Evaluation of the registered population of patients with cirrhosis of the liver of cirrhosis of various etiology in Moscow. Moscow. Materials and methods: Based on the data of the Moscow Department of Healthcare for the drug provision for the period from 2017 to 2019. Тhe population of patients with an established diagnosis of liver (other etiology) was characterized according to ICD-10 code K.74 (K74.0-74.6) according to the International Statistical Classification of Diseases and Related Health Problems of the 10th revision. Results: Over a 4-year period, more than 2 thousand patients with established diagnosis of liver cirrhosis received preferential drug provision in Moscow. The largest part of the population of patients with liver cirrhosis receiving preferential drug provision in Moscow is represented by the patients of age groups 40-59 years old and 60-79 years old, the groups 30-39 years old and 80-99 years old were comparable annually. There was a decrease in the number of patients with liver cirrhosis in the age groups of 30-39 and 18-19 years compared with the base year (2017) by 37% and 57%, respectively. At the same time, in pediatric patients (from the neonatal period to 17 years), there was an intensive increase in patients from 52 to 550% compared to the baseline year (2017).
6 November 2020 in Health Care of the Russian Federation
Introduction. Prevention and treatment of glaucoma, which threatens the development of blindness, is one of the most important medical and social problems facing modern society in the era of value-based health care. However, against the background of a wide selection of prostaglandin-F2α analogs, which have an approximately similar level of decrease in ophthalmotonus, a clinical and economic argumentation is required for the approach when forming a budget for drug treatment of glaucoma. The aim of the study. To assess the burden on the health budget of the city of Moscow when using the fluorinated prostaglandin-F2α analog as compared to other prostaglandin-F2α analogs for the treatment of adult patients with primary open-angle glaucoma. Material and methods. There was studied data on the population of patients with a diagnosis of «glaucoma» receiving medication from the budgetary funds of the city of Moscow. The direct medical costs of healthcare in Moscow were calculated for preparations of prostaglandin-F2α analogs for the treatment of adult patients with primary open-angle glaucoma in various clinical options for 5 years. Results. The use of the fluorinated prostaglandin-F2α analog drug Tafluprost in patients with primary open-angle glaucoma is economically justified, while budget savings in the 5-year horizon amounted to 196,777,224.60 rubles, 12,295,378.28 rubles in the baseline scenario (default appointment). and 116 084 865.02 rubles, and in alternative scenarios (appointment for adverse events on Latanoprost) - 125 113 646.70 rubles, 43 942 565.04 rubles. and 89,609,415.58 rubles, respectively. Conclusion. The inclusion of the drug Tafluprost in the drug supply programs of the Moscow healthcare system will increase the efficiency of the use of financial resources and increase the availability of drug supply.